ArticleActa ortopedica brasileira2025
COST AND QUALITY OF LIFE IN PATIENTS UNDERWENT HIP ARTHROPLASTY IN A BRAZILIAN HOSPITAL.
Article in Acta ortopedica brasileira, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: There are few studies in Brazil evaluating the quality of life and costs of patients undergoing total hip arthroplasty (THA). Purpose: (1) To describe the total cost, quality of life and functional scores of patients undergoing THA in a Brazilian private hospital; (2) to determine preoperative factors associated with quality of life and total cost; and (3) to evaluate the association between cost and quality of life. Methods: Of the 1061 patients included, pre- and peri-operative data, total costs, pre- and post-operative functional scores (HOOS, WOMAC) and quality of life scores (EQ-5D) were collected over 2 years. Results: EQ-5D, HOOS and WOMAC improved from 0.492, 54.5 and 45.2, respectively, to 0.888, 90 and 5.9 at 1-year follow-up, and 0.892, 90.4 and 4.0 at 2-year follow-up. The average cost was R$43,324.22±11,323. Associations were observed between EQ-5D variation and male sex (RM=1.058; p=0.03) as well as age (RM=0.996; p<0.001). No association was found between total cost and EQ-5D. Conclusions: The average cost of patients undergoing THA was R$43,324.22. There was an improvement in quality of life and function, an association between quality of life and male sex and age, however no association was found between total cost and quality of life.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.